Yet Another Tylenol Recall: 2.5 Million Cold Multi-Symptom Nighttime Rapid Release Gelcaps

The fifth recall of a Tylenol product this year is “Tylenol Cold Multi-Symptom Nighttime Rapid Release Gelcaps.” McNeil, a division of Johnson & Johnson, a family company, said the caps had “slightly higher than expected” levels of chlorpheniramine ammonio acetate (CPAA). The recall encompasses roughly 2.5 million packages.

No safety concerns are associated with there being more CPAA than there should be. CPAA is a compound made of two ingredients, chlorpheniramine maleate and sodium starch glycolate. They relieve runny noses and sneezing, and help the product dissolve and release its active ingredients, respectively.

Lot numbers affected by the recall:

Tylenol Cold Multi-Symptom Nighttime Rapid Release Gels 24 RR Gelcaps (AMA277, APA059, APA162, ASA025, APA237, ASA072, ASA208, BAA008; UPC – 300450395245)

Tylenol Cold Multi-Symptom Rapid Release Gels Day/night 12+8 RR Gelcaps (AMF034, BAF005, BAF027, BCF080; UPC – 300450396204)

Tylenol Cold Multi-Symptom Rapid Release Gels Day/night 36+24 RR Gelcaps (BBF001, BCF060, BCF079; UPC – 300450396600)

More info is at mcneilproductrecall.com, which is an entire website the company has set up to inform consumers about which of its products have been taken off the shelves.